Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients

Dexa Medica

Status and phase

Completed

Phase 3

Phase 2

Conditions

Breast Cancer

Treatments

Drug: Placebo DLBS1425

Drug: DLBS1425

Study type

Interventional

Funder types

Industry

Identifiers

NCT01433562

DLBS1425-0310

Details and patient eligibility

About

This is a 2-arm, randomized, double-blind, placebo-controlled study aiming to determine the efficacy and safety of DLBS1425 in combination with anthracyclin-based regimen as a neoadjuvant therapy in subjects with previously untreated stage II or III (operable) breast cancer.

The anthracyclin-based regimen in the study will be either CAF/iv and CEF/iv only. The neoadjuvant anthracyclin-based chemotherapy will be given for 3 cycles. The length of each cycle will be 21-28 days.

Full description

The duration of treatment for each subject will be 63 - 84 days (or 3 cycles). The cycle will be initiated at Day-1 (D1 of the 1st cycle). The subsequent cycles will start on Day-22 (D1 of the 2nd cycle) and Day-43 (D1 of the 3rd cycle). DLBS1425 capsules will be administered orally every day (starting from D1 of each cycle) during the study period. All subjects will be under direct supervision of a medical doctor during the study period.

Clinical and laboratory examinations to evaluate investigational drug's efficacy and safety will be performed at baseline and at the end of every cycle over the study course; whilst breast-CT scan will be performed at baseline and at the end of study course.

In addition, at the end of study, at the discretion of Investigator and subjects' own willingness, subjects with good response to treatment (i.e. RECIST and pathological evaluation are regarded as complete or partial response) may continue their breast-cancer therapy with DLBS1425.

Enrollment

40 patients

Sex

Female

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed stage II or III (operable) primary breast cancer
Having radiologically evaluable and measurable lesion(s) of the primary tumor
Karnofsky performance status 80 %
Normal cardiac function: LVEF > 50 %
Adequate hematological function: Hb ≥ 10.0 g/dL, WBC ≥ 3,000/mm3, ANC ≥ 1,500 /mm3, platelet count ≥ 100,000/mm3
Adequate liver function: ALT ≤ 2.5 times upper limit of normal, total bilirubin level ≤ 1.5 times upper limit of normal
Adequate renal function: serum creatinine ≤ 1.5 times upper limit of normal
Able to take oral medication

Exclusion criteria

Pregnancy or breast feeding subjects
History of previous breast cancer (recurrent breast cancer)
History of other cancer within the past 5 years
Prior systemic treatment for the current breast cancer
Prior preoperative topical treatments for the current breast cancer
Uncontrolled or serious CVD
Known or suspected hypersensitivity to any of the chemotherapeutic agents used in the study
Any other serious disease state or medical condition which judged by investigator could interfere with trial participation or trial evaluation
Concurrent herbal (alternative) medicines or food supplements suspected to have effect on breast cancer disease within 14 days prior to screening
Severe psychological or neurological disorder or dementia that would preclude understanding of the informed consent
Participation in any other clinical studies within 30 days prior to screening